Glaukos Corporation (NYSE: GKOS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Glaukos Corporation to related businesses based on the strength of its profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
42.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 16.4% of Glaukos Corporation shares are owned by company insiders. Comparatively, 9.6% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Glaukos Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Glaukos Corporation Competitors||-101.83%||-92.87%||-30.39%|
Valuation and Earnings
This table compares Glaukos Corporation and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Glaukos Corporation||$114.40 million||$4.52 million||-902.33|
|Glaukos Corporation Competitors||$1.67 billion||$207.58 million||56.85|
Glaukos Corporation’s rivals have higher revenue and earnings than Glaukos Corporation. Glaukos Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and recommmendations for Glaukos Corporation and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Glaukos Corporation Competitors||109||727||1023||10||2.50|
Glaukos Corporation presently has a consensus target price of $47.50, suggesting a potential upside of 76.58%. As a group, “Medical Devices & Implants” companies have a potential upside of 34.52%. Given Glaukos Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos Corporation is more favorable than its rivals.
Glaukos Corporation beats its rivals on 8 of the 12 factors compared.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.